STAAR Surgical (NASDAQ:STAA) Major Shareholder Buys $7,917,309.21 in Stock

STAAR Surgical (NASDAQ:STAA - Get Free Report) major shareholder Broadwood Partners, L.P. purchased 497,631 shares of STAAR Surgical stock in a transaction that occurred on Friday, April 4th. The shares were bought at an average cost of $15.91 per share, with a total value of $7,917,309.21. Following the completion of the transaction, the insider now directly owns 13,194,210 shares of the company's stock, valued at approximately $209,919,881.10. The trade was a 3.92 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Wednesday, April 9th, Broadwood Partners, L.P. bought 8,200 shares of STAAR Surgical stock. The shares were purchased at an average price of $15.08 per share, for a total transaction of $123,656.00.
• On Monday, April 7th, Broadwood Partners, L.P. acquired 138,054 shares of STAAR Surgical stock. The stock was purchased at an average cost of $15.61 per share, with a total value of $2,155,022.94.
• On Wednesday, April 2nd, Broadwood Partners, L.P. bought 31,780 shares of STAAR Surgical stock. The stock was purchased at an average price of $17.43 per share, with a total value of $553,925.40.
• On Monday, March 31st, Broadwood Partners, L.P. acquired 22,189 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.46 per share, for a total transaction of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. acquired 3,620 shares of STAAR Surgical stock. The stock was acquired at an average cost of $17.48 per share, with a total value of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.44 per share, with a total value of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. acquired 108,720 shares of STAAR Surgical stock. The stock was bought at an average cost of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. bought 93,124 shares of STAAR Surgical stock. The shares were bought at an average cost of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The shares were purchased at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. bought 259,316 shares of STAAR Surgical stock. The shares were purchased at an average cost of $17.05 per share, with a total value of $4,421,337.80.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock traded up $1.22 during trading on Friday, hitting $16.79. The company's stock had a trading volume of 1,170,915 shares, compared to its average volume of 790,156. The stock has a market cap of $828.17 million, a price-to-earnings ratio of -40.95 and a beta of 0.75. STAAR Surgical has a 52 week low of $13.50 and a 52 week high of $51.34. The stock has a 50-day moving average price of $17.66 and a two-hundred day moving average price of $24.00.

Remove Ads

Analyst Ratings Changes

A number of research analysts have issued reports on STAA shares. BTIG Research lowered shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 12th. William Blair downgraded STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Stephens reaffirmed an "equal weight" rating and issued a $17.00 price objective on shares of STAAR Surgical in a report on Tuesday, March 18th. Piper Sandler reduced their target price on STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a report on Wednesday, February 12th. Finally, Needham & Company LLC restated a "hold" rating on shares of STAAR Surgical in a research report on Thursday, February 27th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, STAAR Surgical has an average rating of "Hold" and an average price target of $25.29.

Institutional Investors Weigh In On STAAR Surgical

A number of institutional investors have recently made changes to their positions in STAA. Quarry LP bought a new stake in shares of STAAR Surgical in the 3rd quarter valued at $50,000. FMR LLC raised its position in shares of STAAR Surgical by 79.3% in the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock worth $263,000 after acquiring an additional 3,136 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of STAAR Surgical in the 4th quarter valued at about $180,000. HighTower Advisors LLC bought a new stake in shares of STAAR Surgical during the 3rd quarter valued at about $336,000. Finally, Bridgefront Capital LLC grew its stake in STAAR Surgical by 27.2% during the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier's stock worth $262,000 after purchasing an additional 2,306 shares during the period. Institutional investors own 96.70% of the company's stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.